Recent Updates on Investment Analysts' Ratings for RxSight (RXST)

As of March 14, 2025, several investment analysts have provided new insights regarding their ratings and price targets for RxSight (NASDAQ: RXST).

• On February 26, 2025, JPMorgan Chase & Co. reduced its price target for RxSight from $62.00 to $40.00, while maintaining an “overweight” rating.
• Also on February 26, 2025, analysts from Stifel Nicolaus adjusted their price target for RxSight from $35.00 to $33.00, changing their rating to “hold.”
• Wells Fargo & Company also lowered its price target for the company on the same date, from $40.00 to $35.00, and assigned an “equal weight” rating.
• In contrast, Needham & Company LLC reaffirmed their “buy” rating for RxSight, setting a new price target of $43.00 on February 26, 2025.
• Previously, on January 13, 2025, Stifel Nicolaus again lowered its price target from $40.00 to $35.00, maintaining a “hold” rating.
• Wells Fargo & Company similarly revised its target from $42.00 to $40.00 on January 13, 2025, sticking with an “equal weight” designation.
• On the same day, Needham & Company reaffirmed a “buy” rating on the stock, increasing their price target to $66.00.

RxSight's Stock Performance

On Friday, RXST opened at $25.22. The stock shows a one-year low of $24.64 and a one-year high of $66.54. With a market capitalization of $1.02 billion, RxSight has a price-to-earnings ratio of -30.39 and a beta of 1.22. The company's 50-day moving average is $30.76, while the 200-day moving average is $41.40.

On February 25, 2025, RxSight released its quarterly earnings report, revealing earnings per share (EPS) of ($0.15). This underperformed the consensus estimate of $0.10 by ($0.25). The company reported a negative return on equity of 14.00% and a net margin of -23.92%. Total revenue during the quarter reached $40.21 million, slightly below the consensus estimate of $40.23 million. Analysts predict that RxSight will post an EPS of -0.7 for the current year.

Insider Transactions

In recent insider trading news, Director Shweta Maniar sold 3,519 shares of RXST on January 22, 2025, at an average price of $30.87, totaling $108,631.53. After this transaction, Maniar's remaining ownership stands at 7,383 shares, valued at $227,913.21, representing a 32.28% decrease in her stake. The sale was documented in a filing with the SEC.

Conversely, on January 15, 2025, Director Jesse Anderson Corley purchased 1,443 shares at an average price of $31.18 per share, amounting to $44,992.74. After the acquisition, Corley owns approximately 1,443 shares, valued around $44,992.74, indicating an increase in his stock ownership.

Overall, insider ownership in RxSight stands at 9.36%.

Institutional Investor Movements

Numerous institutional investors have also altered their holdings in RxSight recently. Polar Asset Management Partners Inc. acquired a new stake worth $1,606,000 in RxSight during the fourth quarter.

UBS Asset Management Americas LLC boosted its holdings by 23.5% during the same quarter and now owns 84,958 shares valued at $2,921,000 after purchasing an additional 16,140 shares.

Voloridge Investment Management LLC increased its holdings by 138.9% in the fourth quarter as well, now controlling 365,617 shares worth $12,570,000 after acquiring an extra 212,599 shares.

Squarepoint Ops LLC improved its stake by 12.5%, now owning 133,125 shares valued at $4,577,000 following the acquisition of an additional 14,799 shares.

Finally, Tidal Investments LLC bought a new stake valued at $355,000 during the fourth quarter. In sum, hedge funds and other institutional investors hold 78.78% of RxSight's stock.

RxSight, Inc. is a commercial-stage medical device company dedicated to the research, development, manufacturing, and sale of light-adjustable intraocular lenses (LAL) used in cataract surgeries in both the United States and internationally. The RxSight system allows doctors to customize and enhance the visual acuity of patients after cataract surgery.

Investment, Analysts, RxSight